Quest Diagnostics Adds HCV Screening To Its New Obstetrics Test Panel

Quest Diagnostics (DGX) announced the launch of a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people for hepatitis C with other laboratory tests typically ordered during early pregnancy. The company noted that the new test panel follows a Quest Diagnostics Health Trends study with the CDC that revealed less than half of pregnant people are screened for hepatitis C as recommended under guidelines.

Damian "Pat" Alagia, Senior Medical Director, Women's Health, Quest Diagnostics, said: "By adding HCV screening to our obstetrics panel, physicians will be more likely to deliver guideline-based care that reduces HCV infection during pregnancy and fosters a positive outcome for the patient and their newborn."

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT